Print Page  Close Window
10-Q
PARATEK PHARMACEUTICALS, INC. filed this Form 10-Q on 05/09/2018
Entire Document
 

 

Paratek Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

 

For the Three Months Ended

March 31,

 

 

 

2018

 

 

2017

 

Net loss

 

$

(27,750

)

 

$

(27,670

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

187

 

 

 

301

 

Stock-based compensation expense

 

 

4,367

 

 

 

4,044

 

Noncash interest expense

 

 

439

 

 

 

293

 

Change in fair value of contingent consideration

 

 

(15

)

 

 

(231

)

Changes in operating assets and liabilities

 

 

 

 

 

 

 

 

Accounts receivable and other current assets

 

 

4,985

 

 

 

420

 

Purchase of prepaid interest - marketable securities

 

 

(77

)

 

 

 

Accounts payable and accrued expenses

 

 

(1,452

)

 

 

(2,439

)

Other liabilities and other assets

 

 

264

 

 

 

355

 

Net cash used in operating activities

 

 

(19,052

)

 

 

(24,927

)

Investing activities

 

 

 

 

 

 

 

 

Purchase of fixed assets, net

 

 

(24

)

 

 

(897

)

Purchase of marketable securities

 

 

(49,692

)

 

 

(27,665

)

Proceeds from maturities of marketable securities

 

 

31,000

 

 

 

25,000

 

Net cash used in investing activities

 

 

(18,716

)

 

 

(3,562

)

Financing activities

 

 

 

 

 

 

 

 

Proceeds from exercise of stock options

 

 

176

 

 

 

22

 

Proceeds from sale of common stock

 

 

51,516

 

 

 

36,859

 

Net cash provided by financing activities

 

 

51,692

 

 

 

36,881

 

Net decrease in cash, cash equivalents and restricted cash

 

 

13,924

 

 

 

8,392

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

35,828

 

 

 

54,029

 

Cash, cash equivalents and restricted cash at end of period

 

$

49,752

 

 

$

62,421

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

1,077

 

 

$

737

 

Purchases of fixed assets in accrued expenses

 

$

 

 

$

198

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 


 

4